Growdon J H, Corkin S, Huff F J, Rosen T J
Neurobiol Aging. 1986 Jul-Aug;7(4):269-76. doi: 10.1016/0197-4580(86)90007-2.
Nootropics, a new class of drugs believed to activate mental functions, have been proposed as a treatment for clinical disorders in which cognition is impaired. We therefore administered the nootropic drug piracetam, alone and in combination with phosphatidylcholine (PC), to 18 patients with Alzheimer's disease (AD), and measured the effects of treatment on a broad range of cognitive functions. Piracetam was administered according to three double-blind crossover protocols and a replication study that differed in piracetam dose (2.4 to 9.9 g/day) and whether PC (18 g/day) was administered concurrently. The drug was well tolerated, and there were not toxic side effects. Plasma choline levels rose significantly during piracetam and PC administration; monoamine metabolites in cerebrospinal fluid were unaffected by treatment. Piracetam, either alone or in combination with PC, did not significantly affect cognition in the AD group as a whole, nor did it improve test performance in any single patient.
促智药是一类被认为可激活心理功能的新型药物，已被提议用于治疗认知功能受损的临床疾病。因此，我们对18名阿尔茨海默病（AD）患者单独使用促智药吡拉西坦以及将其与磷脂酰胆碱（PC）联合使用，并测量了治疗对广泛认知功能的影响。吡拉西坦按照三种双盲交叉方案及一项重复研究给药，这些方案在吡拉西坦剂量（2.4至9.9克/天）以及是否同时给予PC（18克/天）方面存在差异。该药物耐受性良好，且无毒性副作用。在给予吡拉西坦和PC期间，血浆胆碱水平显著升高；脑脊液中的单胺代谢产物不受治疗影响。吡拉西坦单独使用或与PC联合使用，对整个AD组的认知功能均无显著影响，也未改善任何一名患者的测试表现。
